The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) for the continuous treatment of motor fluctuations in adults with advanced Parkinson’s disease, making it the first subcutaneous, or under-the-skin, apomorphine infusion device approved for this indication. The application from Supernus Pharmaceuticals was the developer’s fourth…
News
Jupiter Neurosciences said it’s planning a Phase 2a clinical trial to test Jotrol, the company’s oral formulation of resveratrol, as a treatment for Parkinson’s disease, in partnership with Zina Biopharmaceuticals. Zina will assist with aspects of the trial protocol, such as identifying biomarkers and selecting sites for the…
A dopamine transporter scan — an exam that visualizes dopaminergic neurons, the nerve cells that are affected in Parkinson’s disease — may help in predicting which patients are at risk of aspiration, when food or liquid enters the lungs instead of the stomach. Dysphagia, which happens when Parkinson’s…
Ncardia has launched a human-derived microglia cell model, called Ncyte Microglia, that the company says may help advance research in Parkinson’s disease and other neurodegenerative conditions — and which may be a tool in the development of new therapies. Microglia are resident immune cells in the brain that…
Parkinson’s disease patients saw an average increase of more than four hours in the duration of their symptom control, without the presence of dyskinesia, with a consistent supply of A-dopamine directly to their brain, according to a small Phase 1/2 clinical study. DIVE-I (NCT04332276)Â tested how safe A-dopamine, a…
Creative arts therapy, or an expressive therapeutic approach that engages people in various creative activities, can reduce anxiety in individuals with Parkinson’s disease and improve their well-being — while potentially lessening their need for healthcare services — according to the results of a small pilot study conducted in Europe.
Several promising strategies for developing therapeutics capable of crossing or bypassing the blood-brain barrier (BBB) offer potential for treating neurological conditions like Parkinson’s disease, but more work is needed to establish their benefits in clinical trials, a review study suggests. Strategies such as direct brain delivery, focused ultrasound, and…
Biotin (vitamin B7) supplementation may offer protection against manganese-induced brain cell damage, according to a recent study. Manganese is a naturally occurring metal that can cause manganism, a condition characterized by parkinsonism-like symptoms, such as tremors and cognitive issues. In the study led by Souvarish Sarkar, PhD, an assistant…
Researchers at the University of Cambridge in the U.K. are developing brain implants using small clusters of lab-grown cells in combination with electrical impulses to rebuild brain circuits worn down in Parkinson’s disease. “Our ultimate goal is to create precise brain therapies that can restore normal brain function in…
Treatment with the anti-seizure medication levetiracetam led to a worsening of Parkinson’s disease symptoms for a woman in Saudi Arabia, according to a case report. The woman was given levetiracetam to prevent seizures after she fell and hit her head, but she soon after experienced deteriorating neurological and motor…
Recent Posts
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s